4523 On Other Exchanges
Symbol
Exchange
4523 is not on other exchanges.

Executive Profile*

Takashi Owa

Vice President, Chief Medicine Creation Officer - Oncology Business Group and Chief Discovery Officer - Oncology Business Group,Eisai Co., Ltd.
AgeTotal Calculated CompensationThis person is connected to 0 board members in 0 different organizations across 1 different industries.

53--

Background*

Takashi Owa serves as Vice President, Chief Medicine Creation Officer - Oncology Business Group and Chief Discovery Officer - Oncology Business Group at Eisai Co. Ltd. and served as its Chief Innovation Officer of Eisai Product Creation Systems. Takashi Owa served as President of Oncology PCU and Chief Scientific Officer of Product Creation Systems at Eisai Co., Ltd.

Corporate Headquarters*

4-6-10, Koishikawa
Tokyo, -- 112-8088

Japan

Phone: 81 3 3817 3016
Fax: 81 3 3811 6032

Board Members Memberships*

There is no Board Members Memberships data available.

Education*

There is no Education data available.

Other Affiliations*

There is no Company Affiliations data available.

Annual Compensation*

There is no Annual Compensation data available.

Stock Options*

There is no Stock Options data available.

Total Compensation*

There is no Total Compensation data available.
*Data is at least as current as the most recent Definitive Proxy.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Howard W. Robin Chief Executive Officer, President and Director
Nektar Therapeutics
$892.6K
Peter M. Hecht Ph.D. Co-Founder, Chief Executive Officer and Director
Ironwood Pharmaceuticals, Inc.
$100.0K
Gyo Sagara Chief Executive Officer, President and Representative Director
Ono Pharmaceutical Co., Ltd.
--
Akira Kurokawa Chief Executive Officer, President, Representative Director, Member of Nominating Committee, Member of Executive Compensation Committee and Member of Corporate Strategy Committee
Santen Pharmaceutical Co. Ltd.
¥94.0M
Eduardo Javier Sanchiz Yrazu Chief Executive Officer, Member of Management Board, Executive Director and Member of Compliance Committee
Almirall, S.A.
€1.1M
Compensation as of Fiscal Year 2015.

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact EISAI CO LTD, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.